NCT00082381已完成3 期
Effect of AC2993 (Synthetic Exendin-4) Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 551
- 试验地点
- 87
- 主要终点
- Change in Glycosylated Hemoglobin (HbA1c)
研究概览
简要总结
This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients have been treated with a stable dose of one of the following for at least 3 months prior to screening:
- •1500 to 2550 mg/day immediate-release metformin (or 1500 to 2000 mg/day extended-release metformin) and at least an optimally effective dose of a sulfonylurea, or
- •a fixed-dose sulfonylurea/metformin combination therapy with the same sulfonylurea and metformin requirements as for the individual components.
- •HbA1c between 7.0% and 10.0%, inclusive.
- •History of stable body weight (not varying by >10% for at least three months prior to screening).
- •Female patients are not breastfeeding, and female patients of childbearing potential (not surgically sterilized and between menarche and 1-year postmenopause)
排除标准
- •Patients are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study.
- •Patients are employed by Lilly or Amylin.
- •Patients have participated in this study previously or any other study using AC2993 or GLP-1 analogs.
- •Patients have participated in an interventional medical, surgical, or pharmaceutical study within 30 days prior to screening. This criterion includes drugs that have not received regulatory approval for any indication at the time of study entry.
- •Patients have had greater than three episodes of severe hypoglycemia within 6 months prior to screening.
- •Patients are undergoing therapy for a malignancy, other than basal cell or squamous cell skin cancer.
- •Patients have cardiac disease that is Class III or IV, according to the New York Heart Association criteria.
- •Patients have a known allergy or hypersensitivity to insulin glargine, AC2993, or excipients contained in these agents.
- •Patients have characteristics contraindicating metformin or sulfonylurea use, according to product-specific label, in the opinion of the investigator.
- •Patients have a history of renal transplantation or are currently receiving renal dialysis or have serum creatinine >=1.5 mg/dL for males and >=1.3 mg/dL for females.
- •Patients have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alanine aminotransferase/serum glutamicpyruvic transaminase greater than three times the upper limit of the reference range.
- •Patients have known hemoglobinopathy or chronic anemia.
- •Patients are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
- •Patients have used any prescription drug to promote weight loss within 3 months prior to screening.
- •Patients have any other condition (including known drug or alcohol abuse or psychiatric disorder) that precludes them from following and completing the protocol, in the opinion of the investigator.
- •Patients fail to satisfy the investigator of suitability to participate for any other reason.
研究组 & 干预措施
Exenatide Arm
Experimental
exenatide subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
干预措施: Exenatide (AC2993) (Drug)
Insulin Glargine Arm
Active Comparator
subcutaneous injection, once daily; forced titration to target blood glucose level
干预措施: Insulin glargine (Drug)
结局指标
主要结局
Change in Glycosylated Hemoglobin (HbA1c)
时间窗: Baseline, week 26
Change in HbA1c from baseline to week 26
次要结局
- Percentage of Patients Achieving HbA1c <=7%(26 weeks)
- Change in Body Weight(Baseline, week 26)
- Change in Fasting Serum Glucose(Baseline, week 26)
- Change in 7-point Self-monitored Blood Glucose (SMBG) Profile(Baseline, week 26)
- Percentage of Patients With Hypoglycemic Events(26 weeks)
- Change in Rate of Hypoglycemic Events(Baseline, week 26)
研究者
研究点 (87)
Loading locations...
相似试验
已完成
3 期
Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and MetforminDiabetes Mellitus, Type 2NCT00082407AstraZeneca505
已完成
3 期
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)Type 2 Diabetes MellitusNCT00308139AstraZeneca303
已完成
3 期
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT00097500AstraZeneca69
已完成
1 期
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese SubjectsOverweightDiabetes Mellitus, Type 2NCT06247748Beijing Dongfang Biotech Co., Ltd.28
已完成
3 期
A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)Type 2 Diabetes MellitusNCT00877890AstraZeneca254